Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

C. Scheid; P. Sonneveld; I.G.H. Schmidt-Wolf; B. van der Holt; L. el Jarari; U. Bertsch; H. Salwender; S Zweegman; [No Value] et al; H.M. Lokhorst

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

C. Scheid, P. Sonneveld, I.G.H. Schmidt-Wolf, B. van der Holt, L. el Jarari, U. Bertsch, H. Salwender, S Zweegman, [No Value] et al, H.M. Lokhorst

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	148-154
Number of pages	7
Journal	Haematologica
Volume	99
Issue number	1
Publication status	Published - 2014

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23996482

Cite this

Scheid, C., Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., et al, N. V., & Lokhorst, H. M. (2014). Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica, 99(1), 148-154. http://www.ncbi.nlm.nih.gov/pubmed/23996482

@article{1bf043804b0a49958e452124e06d1d9b,

title = "Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.",

author = "C. Scheid and P. Sonneveld and I.G.H. Schmidt-Wolf and {van der Holt}, B. and {el Jarari}, L. and U. Bertsch and H. Salwender and S Zweegman and {et al}, {[No Value]} and H.M. Lokhorst",

year = "2014",

language = "English",

volume = "99",

pages = "148--154",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Scheid, C, Sonneveld, P, Schmidt-Wolf, IGH, van der Holt, B, el Jarari, L, Bertsch, U, Salwender, H, Zweegman, S, et al, NV & Lokhorst, HM 2014, 'Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.', Haematologica, vol. 99, no. 1, pp. 148-154. <http://www.ncbi.nlm.nih.gov/pubmed/23996482>

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. / Scheid, C.; Sonneveld, P.; Schmidt-Wolf, I.G.H. et al.
In: Haematologica, Vol. 99, No. 1, 2014, p. 148-154.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

AU - Scheid, C.

AU - Sonneveld, P.

AU - Schmidt-Wolf, I.G.H.

AU - van der Holt, B.

AU - el Jarari, L.

AU - Bertsch, U.

AU - Salwender, H.

AU - Zweegman, S

AU - et al, [No Value]

AU - Lokhorst, H.M.

PY - 2014

Y1 - 2014

M3 - Article

SN - 0390-6078

VL - 99

SP - 148

EP - 154

JO - Haematologica

JF - Haematologica

IS - 1

ER -